Antimetastatic activity of seongsanamide B in γ-irradiated human lung cancer
Ga-Hee Ryoo1, Geum Jin Kim2,3, Ah-Reum Han1
1Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongeup-si, Jeollabuk-do, 56212, South Korea.
Abstract:
Lung cancer, which has a high incidence and mortality rates, often metastasizes and exhibits resistance to radiation therapy. Seongsanamide B has conformational features that suggest it has therapeutic potential; however, its antitumor activity has not yet been reported. We evaluated the possibility of seongsanamide B as a radiation therapy efficiency enhancer to suppress γ-irradiation-induced metastasis in non-small cell lung cancer. Seongsanamide B suppressed non-small cell lung cancer cell migration and invasion caused by γ-irradiation. Furthermore, it suppressed γ-irradiation-induced upregulation of Bcl-XL and its downstream signaling molecules, such as superoxide dismutase 2 (SOD2) and phosphorylated Src, by blocking the nuclear translocation of phosphorylated STAT3. Additionally, seongsanamide B markedly modulated the γ-irradiation-induced upregulation of E-cadherin and vimentin. Consistent with the results obtained in vitro, while seongsanamide B did not affect xenograft tumor growth, it significantly suppressed γ-irradiation-induced metastasis by inhibiting Bcl-XL/SOD2/phosphorylated-Src expression and modulating E-cadherin and vimentin expression in a mouse model. Thus, seongsanamide B may demonstrate potential applicability as a radiation therapy efficiency enhancer for lung cancer treatment.
Insights
Seongsanamide B enhances radiation therapy for lung cancer by inhibiting metastasis. This compound suppresses cell migration and invasion, offering potential as a novel treatment enhancer.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Lung cancer presents high incidence and mortality rates, often complicated by metastasis and radiation resistance.
- Seongsanamide B, a compound with potential therapeutic features, has not been previously studied for its antitumor effects.
- Enhancing radiation therapy efficacy is crucial for improving outcomes in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To investigate Seongsanamide B as a radiation therapy enhancer for suppressing gamma-irradiation-induced metastasis in NSCLC.
- To elucidate the molecular mechanisms by which Seongsanamide B affects radiation-induced cellular processes.
Main Methods:
- In vitro assays evaluating cell migration and invasion following gamma-irradiation.
- Western blot analysis to assess protein expression levels (Bcl-XL, SOD2, p-Src, p-STAT3, E-cadherin, vimentin).
- In vivo studies using a mouse xenograft model to evaluate the effect of Seongsanamide B on tumor growth and metastasis post-irradiation.
Main Results:
- Seongsanamide B significantly suppressed gamma-irradiation-induced migration and invasion of NSCLC cells.
- The compound blocked the nuclear translocation of phosphorylated STAT3, inhibiting the upregulation of Bcl-XL, SOD2, and phosphorylated Src.
- Seongsanamide B modulated the expression of E-cadherin and vimentin, and suppressed metastasis in a mouse model without affecting tumor growth.
Conclusions:
- Seongsanamide B demonstrates potential as a radiation therapy efficiency enhancer for lung cancer.
- Its mechanism involves inhibiting key signaling pathways (STAT3, Bcl-XL/SOD2/Src) and epithelial-mesenchymal transition markers.
- Further research into Seongsanamide B could lead to improved lung cancer treatment strategies.
